Patheon opens European headquarters in Switzerland
pharmafile | November 11, 2008 | News story | Research and Development | Patheon
Contract research organisation Patheon has opened a new European head office
in Zug, Switzerland, near Zurich.
The new headquarters will manage the company's sales, marketing and customer support activities for its pharma industry customers in Europe, co-ordinating the work of sites in France, Italy and the UK.
Certain support functions will be managed in Zug as well, such as procurement and supply chain.
Patheon says it has grown rapidly in Europe through acquisition and organic growth, and until now its sites in France, Italy and the UK have operated independently, but operations will now be harmonised through the head office in Zug.
Wes Wheeler, chief executive and president at Patheon, said: "By moving key European managers to a regional headquarters and centralising the key business functions for our operations across all European sites in one distinct location, Patheon will be more nimble to accelerate growth in the region, enhance profitability and ultimately better serve our clients.
"Patheon's choice of Zug as the headquarters for our European operations is not a coincidence as the city is already home to the Swiss or European headquarters of many of our
pharmaceutical and biotechnology clients. The region has long been well known
as the hub of European biotechnology and pharmaceutical innovation."
The company is relocating key management personnel in Europe to the new headquarters, and will also recruit locally, with 25 people expected to be employed at the site.
Aldo Braca, Patheon's president of Europe, said: "The quality, education-level, and accessibility of a multilingual local labour force is very high in Zug. This coupled with its efficient and business friendly administration makes it an ideal location for our European headquarters."
Related Content
Patheon acquires state-of-the-art manufacturing facility from Roche
Patheon, a provider of drug development and delivery to the pharmaceutical and biopharma sectors, announced …
Patheon completes $2.65 billion merger with DSM
The $2.65 billion merger between Patheon and DSM’s pharma business has completed, creating a new …
Mitsubishi deal to buy Qualicaps will close in March
Mitsubishi Chemical has agreed to buy Qualicaps from US private equity company Carlyle Group in …
